Topic: How To Invest

Wall Street Stock Forecaster Hotline – Friday, November 3, 2017

Article Excerpt

PFIZER INC., $35.55, New York symbol PFE, is one of the world’s leading prescription drugmakers. Its top-selling brands include Lyrica (epilepsy), Celebrex (arthritis pain) and Enbrel (plaque psoriasis, rheumatoid arthritis). The company also makes over-the-counter medications and supplements, including Advil (pain relief), Centrum (vitamins) and Robitussin (cough syrup). Pfizer is in the middle of a strategic review of its consumer business, which supplies 6% of its overall revenue. Depending on the results of the review, the company may opt to sell all or part of that division, or spin it off. It expects to complete the process in 2018. Meantime, Pfizer’s revenue in the three months ended October 1, 2017, rose 0.9%, to $13.2 billion from $13.05 billion a year earlier. That matched the consensus forecast. In February 2017, the company sold its Hospira Infusion Systems business for $900 million. That operation makes intravenous pumps. If you factor out those products and foreign exchange rates, revenue gained 2% in the quarter. Earnings before unusual items…